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Summary
Objectives: To compare the effects of two hyaluronic acid (HA) formulations on mediators of matrix turnover and inﬂammation in an IL-1-
treated cartilageesynovium co-culture model with the aim of elucidating mechanisms by which viscosupplementation exerts beneﬁcial effects
in osteoarthritic joints.
Design: A co-culture model (100 ng/ml interleukin-1b (IL-1b) added to canine synovial and cartilage explants) was used to investigate the ef-
fects of HA on cartilageesynovium interactions. Three concentrations (1, 0.5, and 0.1) of two commercial sources of HA (A: Synvisc
[hylan G-F 20]; B: Hyalgan [sodium hyaluronate]) were used. Co-cultures without IL-1b (negative) or with IL-1b (positive) but neither HA prod-
uct served as controls. The liquid media were collected every 3 days and explants of cartilage and synovium were collected on days 3, 6, and
20. Media and explants were analyzed histologically, biochemically, and immunohistochemically.
Results: Glycosaminoglycan (GAG) content was measured in cartilage explants. GAG content in explants was higher in both HA groups at the
beginning and the conclusion of the study compared to the IL-1b-treated group. GAG content of the media was signiﬁcantly (P< 0.05) lower in
the Synvisc group than all other groups early. The Hyalgan group demonstrated progressively less GAG release later in the study. The ad-
dition of Synvisc did not decrease the matrix metalloproteinase (MMP)-3 concentrations at any point. MMP-3 concentrations were signiﬁcantly
(P< 0.05) lower among the 1 and 0.5 Hyalgan groups on day 20 compared to the IL-1b-treated group. On day 3, prostaglandin E2 con-
centrations were signiﬁcantly (P< 0.05) higher in the IL-1b-treated group compared to other groups. Both HA groups had less nitric oxide
production than the control groups throughout the study.
Conclusions: This study supports two potential mechanisms for viscosupplementation: a biosynthetic-chondroprotective mechanism, with
a possible delay in onset depending on the form of HA; and an anti-inﬂammatory mechanism.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is among the most frequent and symp-
tomatic medical problems for middle-aged and older peo-
ple, afﬂicting an estimated 12% of people aged 25e74 in
the United States1,2. Numerous risk factors for OA have
been identiﬁed3; however, the exact etiology, pathogenesis,
and progression of this disease have yet to be determined.
There has been a shift over the past decade in the con-
ceptualization of OA. It is no longer strictly viewed as
a ‘‘wear and tear’’ biomechanical process, but also seen
in terms of biochemical and molecular events causing in-
ﬂammation and degradation4. This multifactorial concept
stems from the knowledge that cartilage is a dynamic struc-
ture and OA represents a sustained imbalance between
cartilage synthesis and degradation, favoring the latter.
Articular cartilage functions to provide load transmission
across a joint via a relatively frictionless surface. Cartilage
is composed of cells (chondrocytes) surrounded by an ex-
tracellular matrix (ECM). The ECM consists of water, colla-
gen (mainly type 2), proteoglycans (PGs), and an
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is attached via a link protein to hyaluronic acid (HA). This
entire complex is referred to as a PG aggregate. Collagen
forms a matrix of ﬁbers that is interwoven with the network
of HA. In this way, HA acts as a major aggregating factor
between the collagen, PG aggregate, and cartilage struc-
tural network as a whole5.
Synovial ﬂuid contains high concentrations of HA, and HA
in synovial ﬂuid is produced by Type B synoviocytes. HA
plays a key role in determining the viscoelastic properties
of the synovial ﬂuid6. Under low-shear stresses, HA pro-
vides high viscosity and low elasticity (joint lubricant);
when shear stresses become high, HA becomes more elas-
tic and much more efﬁcient at absorbing energy7.
It has been shown that in advanced stages of OA, there is
a more rapid turnover of the ECM and a reduction in all its
major components, including HA8. Although this turnover is
part of the cartilage and synovial tissues’ repair response,
the process within the tissue is ineffective and the degrada-
tive process associated with OA inevitably progresses3.
Further, the turnover is likely responsible for the decrease
in concentration and average molecular weight of the HA
observed in the synovial ﬂuid of OA joints, which results
in a decrease in the viscoelastic properties of the ﬂuid.
If it were possible to maintain the levels of the components
in the ECM, degradation of osteoarthritic cartilage might be
ameliorated. While there are a number of clinically proven4
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sociated with OA, no medical intervention has so far been
shown to halt disease progression or reverse joint damage
in humans9. Intra-articular injection of HA, termed viscosup-
plementation, is a relatively new pharmacologic therapy
that has demonstrated statistically and clinically signiﬁcant
improvement of symptoms in patients with OA10.
HA injected into the joint has a half-life of approximately
20 h when joints are normal and about 12 h when joints
are inﬂamed11e15; however, the beneﬁt of intra-articular
HA therapy has been shown to last for months.
The purpose of this study was to compare the effects of
two HA formulations on mediators of matrix turnover and
inﬂammation in an IL-1-treated cartilageesynovium co-
culture model with the aim of elucidating mechanisms by
which viscosupplementation exerts beneﬁcial effects in
osteoarthritic joints.
We hypothesized that HA would have beneﬁcial effects in
a canine cartilageesynovium explant model with respect to
matrix synthesis and mediators of inﬂammation and degra-
dation. To test our hypothesis, we used a co-culture model,
which has been reported to represent spontaneously occur-
ring OA with respect to gene expression, matrix synthesis,
and mediators of inﬂammation and degradation16e18.
Materials and methods
SAMPLE COLLECTION
Full-thickness articular cartilage and synovium were ob-
tained fromcanine cadavers (n¼ 4) froma local humane soci-
ety after euthanasia performed for reasons unrelated to this
study. Articular cartilage was harvested from the proximal hu-
meral head; synovium was harvested from the stiﬂe joint. All
joints used were judged to be normal based on gross inspec-
tion of articular cartilage, joint capsule, ligaments, andmenisci.
CO-CULTURE
Cartilage (4 mm) and synovial discs (6 mm) were pre-
pared using dermal biopsy punches (Fray products corp.,Buffalo, NY). Synovium explants were placed in 24-well
plates (Becton Dickinson Labware, Franklin Lakes, NJ)
with one explant per well. Filter inserts (0.4 mm pore, Becton
Dickinson Labware) were placed in the 24-well plates, and
cartilage explants from the same dog were placed in the ﬁl-
ter inserts with one explant per insert (Fig. 1). Explants were
cultured in 1 mm of RPMI 1640 medium with 10% fetal calf
serum, antibiotics (Gibco, Grand Island, NY) (RPMI), and
human recombinant interleukin-1b (IL-1b) (100 ng/ml)
(R&D systems Inc., Minneapolis, MN) overnight (12 h) for
equilibration at 37(C with 5% CO2 and 95% humidity. Neg-
ative control samples were cultured in the same media with-
out supplementation with IL-1b.
TREATMENT
The following morning, three different concentrations (1,
0.5, and 0.1) of two commercially available sources of
HA (A: Synvisc [hylan G-F 20]; B: Hyalgan [sodium hyalur-
onate]) were added to the media. The 1 concentration of
HA added to the culture was determined based on the ther-
apeutic volume of HA normally injected into OA knees
(2 ml) divided by the average volume of synovial ﬂuid found
in a knee joint (7 ml)19. The 0.5 and 0.1 concentrations
are in relation to the 1 concentration as summarized in
Table I for the four study groups. Negative control samples
(without IL-1b), representative of normal articular cartilage
and synovium, and positive control samples (with IL-1b),
representative of osteoarthritic articular cartilage and syno-
vium, did not receive HA supplementation.
The plates were incubated at 37(C with 5% CO2 and 95%
humidity for 24 h. The HA-containing media were collected
and all samples, except the negative controls, were cultured
withmedia supplementedwith IL-1basdescribed above. The
media were collected and refreshed every 3 days. Collected
liquid media (representative of joint ﬂuid) were stored at
20(C for subsequent evaluation of concentrations of gly-
cosaminoglycan (GAG), matrix metalloproteinase (MMP)-3,
prostaglandin E2 (PGE2), and nitric oxide (NO).
Cartilage and synovium explants were collected on days
3, 6, and 20. On the days of harvest, cartilage explants wereFig. 1. Schematic diagram (A) and photograph (B) of co-culture model.
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weight) and stored at 20(C for subsequent evaluation of
water content and matrix contents. The other portion was
used for histological analysis.
WATER CONTENT
Harvested cartilage samples were weighed (wet weight),
lyophilized, and then weighed (dry weight) again. Water
content was calculated for each sample as follows:
Water content ð%Þ¼ ½ðWet weightDry weightÞ=Wet weight
100:
GAG ANALYSIS
Total sulfated GAG content of liquid media (as an
indication of catabolism) and cartilage explants (as an
indication of matrix integrity) was quantiﬁed using the
1-9-dimethylmethylene blue (DMMB) spectrophotometric
analysis20. Explant samples were digested in 1.5 ml of di-
gestion solution containing 0.5 mg/ml papain (14 U/mg;
Sigma Chemical Co., St. Louis, MO), 20 mM sodium
phosphate buffer (pH 6.8) and 1 mM EDTA at 60(C over-
night. A 10 ml aliquot of liquid media or digest solution was
mixed with 240 ml of DMMB solution and absorbance read
at 525 nm using a spectrophotometer (Synergy HT, Bio-
Tek Instruments, Inc., Winooski, VT). Bovine tracheal
chondroitin sulfate A was used to construct a standard
curve to determine the GAG concentration of each
Table I
Sample groups
Group names Treatments
Negative control
(untreated group)
RPMI (media alone)
Positive control
(IL-1b treated group)
RPMIþ 100 ng/ml IL-1b
A3: Synvisc (3) 1 Synvisc in 100 ml RPMIþ IL
A2: Synvisc (2) 0.5 Synvisc in 100 ml RPMIþ IL
A1: Synvisc (1) 0.1 Synvisc in 100 ml RPMIþ IL
B3: Hyalgan (3) 1 Hyalgan in 100 ml RPMIþ IL
B2: Hyalgan (2) 0.5 Hyalgan in 100 ml RPMIþ IL
B1: Hyalgan (1) 0.1 Hyalgan in 100 ml RPMIþ ILsample. GAG concentrations in the media are reported
in mg GAG. Explant tissue GAG concentrations were stan-
dardized to tissue dry weight and reported as mg GAG/mg
dry weight.
PGE2 AND MMP-3 ANALYSES
Total PGE2 and MMP-3 content in conditioned media was
determined by enzyme immunoassay systems (Amersham
International, PLC, Buckinghamshire, England) according
to the manufacturer’s protocol. PGE2 concentrations are re-
ported in pg/ml and MMP-3 concentrations are reported in
ng/ml.
NO ANALYSIS
Media NO concentration was determined using the spec-
trophotometric Griess assay (Promega, Madison, WI)
according to the manufacturer’s protocol21. Nitrite (NO2
)
concentrations in the conditioned media were measured.
Culture media (50 ml) were incubated with 50 ml of 1% sulfa-
nilamide at room temperature for 5 min, then 50 ml of 0.1%
N-naphylethylenediamine dihydrochloride in distilled water.
Sample concentrations were determined by measuring the
absorbance at 520 nm (Synergy HT, Bio-Tek Instruments,
Inc., Winooski, VT). Known concentrations of sodium nitrite
were used to construct a standard curve. NO concentra-
tions are reported in mMol.
HISTOLOGY ASSESSMENT
After routine histologic processing, 5-mm cartilage sec-
tions were stained with hematoxylin and eosin (H&E) and
toluidine blue. Sections were evaluated in triplicate by one
investigator (JLC) who was unaware of sample number or
treatment group. Sections were evaluated for histologic
characteristics of viability, cell morphology, and PG stain-
ing. Subjective histologic evaluation was recorded for
each group at each time point.
STATISTICAL ANALYSIS
Sample size for this study was determined by analysis of
variance (ANOVA) sample size analysis by inputting GAG
content as the primary outcome variable and the desiredTable II
Summary of results
GAG media (mg) GAG tissue (mg/mg dry wt.)
3 6 20 3 6 20
Positive control (IL-1b treated group) 75.1 67.9 70.0 89.2 6.91 5.37 63.9 42.6 92.8 51.3 17.8 12.7
Negative control (untreated group) 115 59.4 119 100 2.88 2.22 73.2 15.9 63.4 30.2 28.7 19.6
Sodium hyaluronate
0.1 171 98.3 126 36.4 1.26 1.38 59.8 59.3 47.9 27.3 80.0 47.6
0.5 277 58.2 229 105 1.40 0.521 218 90.0 33.0 20.0 132 129
1 163 116 255 106 4.33 6.85 240 154 76.4 55.6 90.2 78.2
Hylan G-F 20
0.1 8.31 13.1 85.6 73.1 6.07 10.1 222 83.3 36.3 19.2 29.8 16.7
0.5 5.34 10.7 68.1 115 2.49 3.17 131 92.3 69.3 42.9 42.4 15.7
1 28.5 12.0 88.9 102 16.3 11.2 230 107 40.6 26.3 34.0 5.73
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values for GAG content from previous studies using in vitro
explant culture models as data for this analysis, a sample
size of n¼ 4 per treatment group was required for the de-
sired power for this study.
All statistical analyses were performed using SigmaStat
(Jandel Scientiﬁc, San Rafael, CA). Data from all samples
within each group were combined, and medians and
means S.E.M. were determined for each. Comparisons
were made using a t test or one-way ANOVA for continuous
data. Where signiﬁcant differences among groups were
detected, an all-pairwise multiple comparison procedure
(Tukey test) was performed to determine which groups
were signiﬁcantly different from one another. A Kruskale
Wallis one-way ANOVA on ranks was used to compare
categorical data. A Spearman rank correlation test was
used for determining if signiﬁcant correlations among the
data existed. Signiﬁcance was set at P< 0.05.
Results
All results are summarized in Table II. Table III summa-
rizes the effects of HA treatment on each of the tested
variables.
GAG CONTENT AND LOSS
All groups contained measurable concentrations of GAG
at all collection times. Although the differences were not sta-
tistically signiﬁcant, GAG content in cartilage explants
was higher in both HA groups (hylan G-F 20 and sodium hy-
aluronate) at the beginning (day 3) [Fig. 2(A)] and at the
conclusion of the study (day 20) [Fig. 2(B)] compared to
the IL-1b-treated (positive control) group. There were no
signiﬁcant differences in GAG content between the two
HA groups. No signiﬁcant differences were noted among
the various concentrations. The untreated (negative control)
group had more GAG content at the conclusion of the study
compared to the IL-1b-treated group.
GAG concentrations in the liquid media were also mea-
surable at all collection times. The GAG content of the media
was signiﬁcantly (P< 0.05) lower in the Synvisc group than
all other groups on day 3 [Fig. 2(C)]. No signiﬁcant differ-
ences among the concentrations within this group were
seen. On day 9, all concentrations in the Hyalgan group
had signiﬁcantly (P< 0.05) higher GAG concentrations inthe media compared to the untreated group. On day 12, me-
dia from the 1 and 0.5 Hyalgan groups had signiﬁcantly
(P< 0.05) higher GAG concentrations than the positive
and negative controls. However, the Hyalgan group demon-
strated a trend of progressively less GAG release late in the
study period (after day 15), with the lowest media concentra-
tions of all groups by the end of the study (day 20).
MMP-3 CONCENTRATIONS
The IL-1b-treated group had higher MMP-3 concentra-
tions compared with the untreated group on days 3, 9, 12,
15, and 20. The addition of Synvisc did not decrease the
MMP-3 concentrations at any point in the study. On the
other hand, MMP-3 concentrations in the liquid media
were signiﬁcantly (P< 0.05) lower among the 1 and
0.5 Hyalgan groups on day 20 compared to the IL-1b-
treated group [Fig. 2(D)]. No other statistically signiﬁcant
differences among groups or within groups were noted.
PGE2 CONCENTRATIONS
The PGE2 concentrations were measurable in all groups
at all collection times. On day 3, PGE2 concentrations were
signiﬁcantly (P< 0.05) higher in the IL-1b-treated group
compared to the untreated group, all concentrations of the
Hyalgan group, and the 0.1 and 1 concentrations of
the Synvisc group [Fig. 2(E)]. In general, PGE2 concentra-
tions were highest at the collection period immediately fol-
lowing IL-1b exposure. Also, the HA groups and IL-1
treated group had more PGE2 production than the untreated
group throughout the study. The highest concentrations of
PGE2 were detected in groups that had been exposed to
IL-1b during the ﬁrst 6 days of culture.
NO CONCENTRATIONS
NO concentrations were measurable in all groups at all
collection times. The overall trend seen was that both HA
therapy groups had less NO production than the IL-1
b-treated or untreated groups throughout the study period.
This observation was best illustrated on days 12 [Fig. 2(F)]
and 15, when the NO concentrations were signiﬁcantly
(P< 0.05) higher in both the IL-1b-treated and untreated
groups compared to all concentrations of both HA groups,
except in the 0.1 Synvisc group on day 15. This trend con-
tinued through the last day of collection (day 20) with the NOTable II
(continued)
MMP-3 (ng/ml) PGE2 (pg/ml) NO (mMol)
Day
3 6 20 3 6 20 3 6 20
1.177 0.181 0.787 1.573 0.482 0.230 172,863 39,214 97,114 59,230 4226 1992 2726 447 1267 568 636 68.8
0.105 2.189 1.043 2.086 0.088 0.067 31,683 32,542 7636 8194 2325 271 1546 585 1437 772 673 168
0 5.991 3.821 1.262 2.524 76,555 70,040 98,201 114,791 4812 3088 2580 467 1304 290 276 51.6
0 8.000 10.30 0 51,397 27,643 158,400 123,057 5826 5306 2605 983 1287 431 302 196
0 3.438 2.703 0 39,119 31,202 182,615 188,548 6482 6941 2653 903 1873 1068 460 221
2.117 1.804 5.592 5.451 0.633 0.448 57,928 46,864 67,769 9822 5053 4702 2322 893 1056 246 398 119
0 8.521 4.966 1.289 2.031 130,061 44,374 94,962 24,501 4883 4667 3641 1457 1348 728 329 135
1.196 2.393 1.935 1.604 0.463 0.498 79,133 36,253 108,581 44,859 3887 5004 1548 510 1504 503 268 71.0
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Effect of HA therapy on GAG content in tissue, GAG content of the liquid media, PGE2 concentrations, NO concentrations, and MMP-3
concentrations
GAG tissue GAG media PGE2 NO MMP-3
Synvisc
(hylan G-F 20)
[ than
IL-1b-treated group
early (day 3)
and late (day 20)
Y than
IL-1b-treated
group early
Y than
IL-1b-treated group
early (day 3)
Y than
IL-1b-treated group
throughout study
No effect
Hyalgan
(sodium hyaluronate)
[ than
IL-1b-treated group
early (day 3) and
late (day 20)
[ than
IL-1b-treated
group early, later
Y (after day 15)
Y than
IL-1b-treated
group early (day 3)
Y than
IL-1b-treated group
throughout study
Y than
IL-1b-treated group
late (day 20)concentrations signiﬁcantly (P< 0.05) higher in the un-
treated group than both HA groups, and the OA group NO
concentrations signiﬁcantly (P< 0.05) higher than the 0.1
Hyalgan group and the 0.5 and 1 Synvisc groups. NO
concentrations were not signiﬁcantly different among the un-
treated and IL-1b-treated groups at any time point.
HISTOLOGIC EVALUATION
Subjectively, histologic assessment of matrix staining
corresponded well to GAG content in the explants. Day 3
explants had the most intense PG (T-blue) staining, andintensity of staining diminished in all groups over time. Sub-
jective differences in PG staining were seen among groups
at each time point evaluated. On day 3, the most intense
staining was noted in the 0.5 and 1 Hyalgan groups
and all three Synvisc groups. On day 6, the most intense
staining was seen in the 0.5 and 1 Hyalgan and 0.5
and 1 Synvisc groups. In addition, the untreated group
had subjectively more intense staining than the IL-1b-
treated group. On day 20, all three Hyalgan groups had
more intense staining than all other groups, and all three
Synvisc groups and the untreated group had more intense
staining than the IL-1b-treated group (Fig. 3). Subjectively,Fig. 2. (A) MeanSD concentrations of GAG in cartilage explants on day 3. GAG content in cartilage explants was higher in both HA groups
(hylan G-F 20 and sodium hyaluronate) compared to the IL-1b treated group after 3 days. (B) MeanSD concentrations of GAG in cartilage
explants on day 20. GAG content in cartilage explants was higher in both HA groups compared to the IL-1b treated group at the conclusion of
the study. (C) MeanSD concentrations of GAG in liquid media on day 3. GAG content of media was signiﬁcantly (P< 0.05) lower in the
Synvisc group than all other groups on day 3. (D) Mean SD concentrations of MMP-3 in liquid media on day 20. MMP-3 concentrations
were signiﬁcantly (P< 0.05) lower among the 1 and 0.5 Hyalgan groups compared to the IL-1b treated group. (E) MeanSD concentra-
tions of PGE2 in liquid media on day 3. PGE2 concentrations were signiﬁcantly (P< 0.05) higher in the IL-1b treated group compared to the
untreated group, all concentrations of the Hyalgan group, and the 0.1 and 1 concentrations of the Synvisc group. (F) MeanSD concen-
trations of NO in liquid media on day 12. NO concentrations were signiﬁcantly (P< 0.05) higher in both the IL-1b treated and untreated groups
compared to all concentrations of both HA groups.
819Osteoarthritis and Cartilage Vol. 14, No. 8Fig. 3. Photomicrographs showing appearance of cartilage explants from treatment groups after 20 days in co-culture. Subjectively, the
Hyalgan groups (A) had more intense staining than all other groups, and the Synvisc groups (B) and the untreated group (C) had more intense
staining than the IL-1b treated group (D) (Toluidine blue stain, original magniﬁcation 10.)no differences in histologic characteristics of cell density or
morphology were noted among any groups at any time
point.
Discussion
Recently, we have reported the use of a co-culture model
for the in vitro study of OA16e18. In order to validate this
model for application to spontaneously occurring OA, we
have compared articular cartilage and synovial tissuesfrom dogs that had no evidence of OA and dogs that had
OA to cartilage and synovial explants co-cultured in
100 ng/ml of IL-1b (Cook et al. 2005, unpublished data
in concurrent review). This co-culture model allows for in-
depth evaluations of cartilage and synovium, and can be
used to create a relatively comprehensive picture of sponta-
neously occurring OA in dogs. The present study sought to
employ this co-culture model to investigate the mechanism
of HA therapy in OA. Intra-articular HA is indicated for
the treatment of pain in OA of the knee23. There are several
820 D. D. Greenberg et al.: Biochemical effects of two different HA productscommercially available forms of HA, differing in regard to
treatment regimens, total dosing, and average molecular
weights10,23. Hylan G-F 20 has an average molecular
weight (MW) of 6 million Da, whereas sodium hyaluronate’s
average MW is between 0.5 and 0.8 million Da. Of note, the
average MW of healthy adult synovial ﬂuid is between 4 and
5 million Da.
HA preparations have been reported to improve symp-
toms and rating scores and decrease the use of nonsteroi-
dal anti-inﬂammatory medications in patients with OA. The
majority of the evidence suggests that intra-articular admin-
istration of HA improves symptoms of OA in selected
patients and has few side effects24e28.
As mentioned above, it is unlikely that the sustained ben-
eﬁcial effects of HA therapy can be accounted for only by
a temporary restoration of the synovial ﬂuid lubrication
and viscoelasticity6. It is more plausible that HA therapy
has disease-modifying biological activity and an impact on
OA progression. There are four potential mechanisms of
action of HA described in the literature that could account
for the beneﬁcial effects seen clinically.
The ﬁrst mechanism is restoration of elastic and viscous
properties of the synovial ﬂuid. Because our model does not
include assessment of HA molecular weight, concentration,
or evaluation of media viscoelastic properties, this study
was not able to investigate this potential mechanism of ac-
tion. In an in vitro model, using media as a representation
of synovial ﬂuid, data regarding the viscoelastic properties
of culture media would be, at best, a poor extrapolation of
the clinical situation. Therefore, new studies in our labora-
tory are aimed at addressing the effects of HA on viscous
and elastic properties using in vivo models.
The second potential mechanism may be derived from
the biosynthetic-chondroprotective effects of exogenous
hyaluronans on cells. Hyaluronans can induce the endoge-
nous synthesis of HA by synovial cells, stimulate chondro-
cyte proliferation, and inhibit cartilage degradation
(chondroprotection)6,29e33.
In the present study, the elevated GAG content in the
HA-treated cartilage tissue at the conclusion of the study
compared to the IL-1b-treated group supports a biosyn-
thetic-chondroprotective mechanism. These results are con-
sistent with numerous prior reports in animal models of OA
that suggest that hyaluronan therapy has chondroprotective
effects32,34,35. Larsen et al. conﬁrmed that chondrocyte in-
jury and matrix degeneration in cartilage explants subjected
to IL-1, degradative enzymes, and oxygen-derived free
radicals were reduced by HA treatment36. Furthermore,
enhanced PG synthesis has been demonstrated37,38.
Higher concentrations of GAG in the liquid media (repre-
sentative of joint ﬂuid) may either indicate PG degradation
in the cartilage explants and subsequent loss of degraded
PG (GAG) to the liquid medium, or release of newly synthe-
sized PGs.
We observed several trends regarding GAG liquid media
concentrations: (1) the Synvisc group had less GAG in the
media than the other groups early on; (2) the Hyalgan group
had more GAG release than all other groups early on (up to
day 15); and (3) the Hyalgan group demonstrated a trend of
progressively less GAG release late in the study period
(after day 15), with the lowest media concentrations of all
groups by the end of the study (day 20).
The decreased concentration of GAG in the media in the
hylan G-F 20 treatment group coupled with tissue GAG con-
centrations similar to the untreated group implies decreased
GAG degradation (chondroprotection). Samples treated
with sodium hyaluronate did not have lower media GAGconcentrations until late in the study period. This may be due
to a delayed therapeutic effect with this speciﬁc form of HA.
Enzymatic activity plays an important role in OA. Takaha-
shi and colleagues found that HA therapy down-regulated
MMP-3 expression in the synovium of rabbits with mild/early
OA32. In the present study, as the concentration of GAG
in the media of Hyalgan treatment groups decreased, so
did the concentrations of MMP-3 in media. This implies
that the decreased release of GAG seen with Hyalgan,
may be due in part to decreased expression and activity of
degradative enzymes. However, signiﬁcant reductions in
media MMP-3 concentrations were not observed for Synvisc
samples, indicating that hylan G-F 20 treatment did not
affect the expression of this degradative enzyme (MMP-3)
in this study. Future studies are required to deﬁnitively deter-
mine if chondroprotective effects of HA are the result of
decreased degradation, increased synthesis, or both.
The anti-inflammatory effects that have been observed
with HA suggest another potential mechanism. HA therapy
has been associated with decreases in inﬂammatory cell
count in the synovial ﬂuid, modulating cytokine expression,
and reducing superoxide radicals23. NO and PGE2 are
markers of inﬂammation associated with chondrodegrada-
tion. Takahashi et al. showed that NO production by the me-
niscus and synovium was reduced by the administration of
HA39. HA has also been shown to suppress synovial cell
release of PGE2 secondary to IL-1a activation
40,41. In the
current study, PGE2 and NO concentrations were increased
after IL-1b stimulation (IL-1b-treated group) compared to
the HA or untreated groups. As these are both inﬂammatory
markers, HA therapy appears to modulate the inﬂammatory
process seen in OA.
PGE2 concentrations were highest at the collection pe-
riod immediately following IL-1b exposure, results consis-
tent with prior work in our laboratory22. The decline in
PGE2 concentrations appeared to coincide with the loss
of cell viability after exposure to IL-1b. The cell loss may
have resulted in less PGE2 production secondary to the
smaller number of cells present to respond. This theory ap-
pears to be supported by the correlations between declining
PGE2 concentrations and GAG content and loss.
Finally, there is evidence to support an analgesic effect of
hyaluronan42,43.
Pozo et al. reported that intra-articular HA reduced nerve
impulse activity in nociceptive afferent ﬁbers in a cat model
of acute arthritis44.
There are several limitations to our study. Our in vitro
model does not account for load, blood ﬂow, joint function,
or pain. This limited us to investigating only two of the four po-
tential mechanisms outlined in the literature. The concentra-
tions of HA used were based on the best available data. No
signiﬁcant differences were noted among the concentrations
in any of the variables tested. Thus, we are conﬁdent that the
range of concentrations used was representative of in vivo
conditions. Based on the broad spectrum of potential mech-
anisms investigated, we were limited in the number of as-
sessments we were able to perform. Therefore, we could
not make deﬁnitive conclusions regarding the clinical effects
of HA or differences among HA products. Ongoing studies in
our laboratory are aimed at further deﬁning the mechanisms
of action of HA therapy from molecular to clinical levels.
Conclusion
This study supports two potential mechanisms of action
of viscosupplementation. The ﬁrst is a biosynthetic-
chondroprotective mechanism, with possibly a delay in
821Osteoarthritis and Cartilage Vol. 14, No. 8onset depending on the form of HA. The second is an anti-
inﬂammatory mechanism of action. In addition to providing
mechanistic evidence, the outcomes in this study further
validate the co-culture model for the investigation of OA. In-
sight into the mechanisms and biological effects of hyalur-
onans may serve as a guide toward future therapy.
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